Capetti AF, et al. - The present work seeks to provide the 48-week update of a previously reported study, concerning a retrospective-prospective follow-up of subjects who had been switched for any reason to a dual combination of dolutegravir (DTG) plus darunavir/ritonavir (DRV/r). Findings suggested that switching to DTG plus DRV/r was safe. This suppressed viral replication without metabolic impact.